m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02977)
Name
C 82
Synonyms
N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82
    Click to Show/Hide
Status
Phase 1/2
Structure
Formula
C8H7ClN4
InChI
1S/C8H7ClN4/c9-6-1-3-7(4-2-6)11-8-5-10-13-12-8/h1-5H,(H2,10,11,12,13)
InChIKey
IUTZKZLVPUPHDA-UHFFFAOYSA-N
PubChem CID
75202656
TTD Drug ID
D0DA5M
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Beta-catenin (CTNNB1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for C 82. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for C 82. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for C 82. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). [2], [4]
RNA binding protein X (RBMX)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for C 82. The RNA binding protein X (RBMX) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). [2], [5]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for C 82. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). [2], [4]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for C 82. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). [2], [6]
CREB-binding protein (CREBBP)
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary CREB-binding protein (CREBBP) is a therapeutic target for C 82. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of C 82 through regulating the expression of CREB-binding protein (CREBBP). [7], [8]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary CREB-binding protein (CREBBP) is a therapeutic target for C 82. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of C 82 through regulating the expression of CREB-binding protein (CREBBP). [8], [9]
References
Ref 1 FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting Beta-catenin through mRNA demethylation. Mol Carcinog. 2018 May;57(5):590-597. doi: 10.1002/mc.22782. Epub 2018 Feb 1.
Ref 2 Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/Beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463. doi: 10.1371/journal.pone.0107463. eCollection 2014.
Ref 3 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 4 Ethionine-mediated reduction of S-adenosylmethionine is responsible for the neural tube defects in the developing mouse embryo-mediated m6A modification and is involved in neural tube defects via modulating Wnt/Beta-catenin signaling pathway. Epigenetics Chromatin. 2021 Dec 4;14(1):52. doi: 10.1186/s13072-021-00426-3.
Ref 5 N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 2017 Jun 2;45(10):6051-6063. doi: 10.1093/nar/gkx141.
Ref 6 Loading MicroRNA-376c in Extracellular Vesicles Inhibits Properties of Non-Small Cell Lung Cancer Cells by Targeting YTHDF1. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820977525. doi: 10.1177/1533033820977525.
Ref 7 N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 2015 Jun 4;161(6):1388-99. doi: 10.1016/j.cell.2015.05.014.
Ref 8 Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11.
Ref 9 N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014 Jan 2;505(7481):117-20. doi: 10.1038/nature12730. Epub 2013 Nov 27.